Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Plasmacytoma × Injections, Subcutaneous × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Other hematologic neoplasm 1

Conditions

Plasmacytoma 1 Paraproteinemias 1 Multiple Myeloma 1 Leukemia, Plasma Cell 1

Interventions

milatuzumab 1 filanesib 1 Thalidomide 1 Steroids 1 Injections, Subcutaneous 1 Immunotherapy, Adoptive 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡